Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 8-K (Current Report)
Date of Report: November 5, 2025
Reporting Period: Single event date (November 5, 2025)
Business Context: The registrant is an emerging growth company incorporated in Delaware, trading on the Nasdaq Capital Market. The filing reports a specific operational update regarding its CyPath® Lung test.
Key Financial Metrics
This Form 8-K does not contain audited financial statements, revenue figures, profit data, cash flow, margins, debt levels, or liquidity metrics. The filing is limited to reporting a specific corporate event.
Material Changes
- Operational Update: The company announced month-over-month growth in CyPath® Lung test volume.
- Comparison: No quantitative comparison to prior periods is provided in the text of this filing; only the direction of growth (month-over-month) is stated.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) detailing the growth in test volume but does not include forward-looking guidance, specific outlook projections, or detailed risk factors within the body of this report.
Unusual Items: None reported in this filing.
Investor Verification Checklist
- Review Exhibit 99.1 (the attached press release) for specific quantitative data regarding the month-over-month growth in CyPath® Lung test volume.
- Verify the impact of this volume growth on future revenue projections, as no financial impact is quantified in this 8-K.
- Confirm the company's status as an emerging growth company and its implications for financial reporting standards.